Deferiprone
- Generic Name
- Deferiprone
- Brand Names
- Ferriprox, Deferiprone Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C7H9NO2
- CAS Number
- 30652-11-0
- Unique Ingredient Identifier
- 2BTY8KH53L
Overview
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Background
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Indication
Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload.
Associated Conditions
- Transfusional Iron Overload
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/11/03 | Phase 2 | Recruiting | Rohan Dharmakumar | ||
2021/11/08 | Phase 2 | Recruiting | University Hospital, Bordeaux | ||
2019/12/03 | Early Phase 1 | UNKNOWN | |||
2019/01/14 | Phase 2 | Completed | |||
2018/11/27 | Phase 1 | Recruiting | |||
2018/07/19 | Phase 4 | Completed | |||
2017/09/26 | Phase 2 | Active, not recruiting | University Hospital, Lille | ||
2017/07/31 | Phase 2 | Completed | |||
2016/12/02 | Phase 1 | Completed | SocraTec R&D GmbH | ||
2016/08/29 | Phase 2 | UNKNOWN |
FDA Approved Products
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|---|---|---|---|---|
ORAL | 500 mg in 1 1 | 2021/08/14 | 10122-100 | ||
ORAL | 1000 mg in 1 1 | 2023/08/01 | 0054-0711 | ||
ORAL | 500 mg in 1 1 | 2023/08/01 | 0054-0576 | ||
ApoPharma USA, Inc. | ORAL | 1000 mg in 1 1 | 2011/04/27 | 52609-0007 | |
ORAL | 1000 mg in 1 1 | 2023/07/27 | 10122-103 | ||
ORAL | 1000 mg in 1 1 | 2023/07/27 | 10122-104 | ||
ORAL | 500 mg in 1 1 | 2023/07/27 | 10122-100 | ||
ApoPharma USA, Inc. | ORAL | 500 mg in 1 1 | 2011/04/27 | 52609-0006 | |
ORAL | 100 mg in 1 mL | 2021/01/05 | 10122-101 | ||
ORAL | 500 mg in 1 1 | 2025/05/19 | 51672-4196 |
EMA Approved Products
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|---|---|---|---|---|---|---|---|
EMEA/H/C/000236 | Italy | N/A | Authorised | 1999/08/25 | N/A | 32 | ||
EMEA/H/C/004710 | Germany | Generic | Authorised | 2018/09/19 | 2018/07/26 | 7 |
HSA Approved Products
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. |
|---|---|---|---|---|---|
TABLET, FILM COATED | 500mg | 2002/09/25 | SIN12083P | ||
SOLUTION | 100.00g/l | 2009/06/26 | SIN13668P |
NMPA Approved Products
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|---|---|---|---|---|---|---|---|---|
国药准字HJ20140379 | 片剂 | 奥贝安可 | 0.5g | Chemical Drug | Approved | 2024/05/30 | Import | ||
H20140379 | 片剂 | 奥贝安可 | 0.5g | Chemical Drug | Expired | 2019/07/18 | Import | ||
H20170053 | apotex inc., richmond hill site | 口服溶液剂 | N/A | 1ml:100mg | Chemical Drug | Expired | 2017/02/10 | Import |
PPB Approved Products
Product Name | Registration Code | Company | Category | Sale Type | Reg. Date |
|---|
No PPB products found
No PPB products found for this drug
TGA Approved Products
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|---|---|---|---|---|
93946 | Active | 2003/04/09 | deferiprone | ||
125666 | Active | 2008/03/26 | deferiprone | ||
125665 | Active | 2008/03/26 | deferiprone | ||
280204 | Active | 2017/07/06 | deferiprone |